Evonik has acquired Spain’s InnovativeHealth Group (InnoHealth) on undisclosed terms and incorporated it into the Care Solutions business line.
Evonik has closed the $640 million acquisition of PeroxyChem from One Equity Partners, after a lawsuit to block it filed by the Federal Trade Commission in August 2019 was rejected.
Evonik and nine partners in the ROMEO (Reactor Optimisation by Membrane-Enhanced Operation) project have succeeded in developing catalysing oxo reactions, in which olefins are converted into aldehydes with synthesis gas in a hydroformylation reaction.
Evonik and Siemens have launched their joint research project Rheticus II, which seeks to develop an efficient and powerful test plant that will develop speciality chemicals from CO2, water, renewable electricity and bacteria.
Evonik has carried out the ‘Future(s) of the Specialty Chemicals Industry’ project, which it claims to be the largest study ever conducted using scenario planning in the sector.